Silo Pharma (SILO) 10-K2021 FY Annual report

Filed: 28 Mar 22, 4:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accelerate, add, Albert, Alzheimer, appendix, arthritic, arthritogenic, Austin, bifurcation, Biographical, Bistro, blood, Buyer, closer, contrary, convey, coupon, DatChat, debit, duly, Einstein, elongation, embedded, epidemic, evolved, fifteen, freestanding, function, herewith, Home, homing, host, impede, implicit, incremental, Index, inflammation, inflammatory, Inline, Interactive, intercompany, interrupt, IP, JV, ketamine, Kirkland, Kou, Kuo, Lake, leaving, licensee, Linkbase, liposomal, liposome, literacy, loading, Munoz, notified, Notwithstanding, od, omitted, opening, page, parent, peptide, pertinent, premium, procced, Prucalopride, quarantine, quorum, ratably, ratio, recession, redacted, resume, resumed, rheumatoid, ROU, Schema, simpler, skillset, spread, standing, sublicensee, Subtopic, talent, Taxonomy, thereunto, therewith, transition, typically, unaffected, uncured, undersigned, upfront, XBRL, ZTI, Zyl, Zylo

Removed: accrue, analyzed, APA, approximated, assessing, avoid, book, branding, CFO, confirming, contractor, coupled, covenant, culture, curtail, deductible, discrepancy, divided, formula, indefinite, inspired, instrumental, intangible, investee, lending, list, Lust, Managing, marketability, max, neglect, Nevada, observe, obsolescence, occurrence, Oncall, permanent, priced, pro, quote, rata, ready, realizable, realization, recording, recoverability, redeem, redeemable, reduction, relationship, representing, reserve, restatement, reversal, reversed, saleable, Schneider, senior, sum, supply, unamortized, unbonded, undiscounted, unstayed, unvacated, utilized, utilizing, Whalehaven, writ

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SILO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Statement of Chief Executive Officer and Chief Financial Officer

Pursuant to Section 1350 of Title 18 of the United States Code

Pursuant to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Eric Weisblum, the Chief Executive Officer and Chief Financial Officer, of Silo Pharma, Inc. (the “Company”), hereby certifies that based on the undersigned’s knowledge:

The Company’s Annual Report on Form 10-K for the period ended December 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 28, 2022	/s/ Eric Weisblum
	Eric Weisblum
	Chief Executive Officer and Chief Financial Officer
	(Principal Executive Officer and Principal Financial and Accounting Officer)